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Efficacy of dose-reduced lenalidomide in patients with
refractory or recurrent multiple myeloma
Effizienz von niedrig-dosiertem Lenalidomid bei Patienten mit
refraktärem oder rezidiviertem Multiplen Myelom
Abstract
Purpose: Introduction of lenalidomide has expanded the therapeutic
options for refractory and recurrent multiple myeloma (MM) patients.
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However,theapplicationoftheapproveddosesmaybedifficultinsome
patients due to adverse effects. Marcus Gorschlüter
1
Axel Glasmacher
1 Experimental design: Therefore, we evaluated the efficacy and safety
of lenalidomide in 10 patients with relapsed and refractory MM who Ingo G. H.
Schmidt-Wolf
1 received a reduced dose due to leukopenia (4), polyneuropathy (1),
musclecramps(1),thrombocytopenia(1),renalinsufficiency(1),atthe
German Refractory
Myeloma Study Group
request of patient (1), as continuous therapy (1), either from the begin-
ning (2) or during treatment (8). They received lenalidomide at a mean
(median) daily dose of 14 (15) mg/d once a day (days 1–21 every
28days)incombinationwithdexamethasoneatamean(median)dose
of 17.6 (28) mg per day (4–40 mg) on days 1–4, 9–12 and 17–20.
1 Department of Internal
Medicine III, Center for
Results: Mean (median) duration of treatment with lenalidomide was
15.1(15)months.Partialresponseorbetterwasreportedinsevenand
Integrated Oncology (CIO),
Universitätsklinikum Bonn,
Germany minimalresponseorbetterwasreportedineightpatients.Mean(medi-
an)valuesfortime-to-progression(TTP)andforprogression-freesurvival
(PFS) were 8.7 (4) months. Mean overall survival (OS) has not been
reached, all patients are still alive.
Conclusion: In conclusion, dose-reduced lenalidomide is an effective
and well tolerated treatment for patients with recurrent or refractory
MM who cannot tolerate full doses.
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Zusammenfassung
Hintergrund: Die Einführung von Lenalidomid hat die therapeutischen
MöglichkeitenfürPatientenmitrefraktäremoderrezidiviertemMultiplen
Myelom(MM)erweitert.AllerdingsistdieAnwendungderzugelassenen
Dosierung bei einigen Patienten aufgrund unerwünschter Wirkungen
schwierig.
ExperimentellesDesign:DeshalbhabenwirdieWirksamkeitundSicher-
heitvonLenalidomidbei10Patientenmitrezidiviertemundrefraktärem
MMausgewertet,dieeinereduzierteDosiserhieltenwegenLeukopenie
(4), Polyneuropathie (1), Muskelkrämpfen (1), Thrombozytopenie (1),
Niereninsuffizienz(1),aufWunschdesPatienten(1),alsDauertherapie
(1), entweder von Anfang an (2) oder während der Behandlung (8). Sie
erhielten Lenalidomid mit einer mittleren (medianen) Tagesdosis von
14 (15) mg/d. einmal pro Tag (Tag 1–21 alle 28 Tage) in Kombination
mit Dexamethason in einer mittleren (medianen) Dosis von 17,6 (28)
mg pro Tag (4–40 mg) an den Tagen 1–4, 9–12 und 17–20.
Ergebnisse:Diemittlere(mediane)DauerderBehandlungmitLenalido-
midbetrug15,1(15)Monate.PartiellesAnsprechenoderbesserwurde
insieben,minimalesAnsprechenoderbesserwurdebeiachtPatienten
berichtet. Mittel-/(Median)werte für das Fortschreiten der Erkrankung
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bei 8,7 (4) Monaten. Die mittlere Überlebenszeit wurde nicht erreicht:
Alle Patienten leben noch.
Fazit: Zusammenfassend ist Lenalidomid eine wirksame und gut ver-
trägliche Behandlung auch für Patienten mit rezidiviertem oder refrak-
tärem MM, die die volle Dosierung nicht tolerieren können.
Schlüsselwörter: Myelom, Lenalidomid, Dexamethason, Lymphom,
Behandlung
Introduction
The immunomodulatory agent lenalidomide (CC-5013)
is a potent thalidomide analog with a different toxicity
profile from the parent molecule. It induces apoptosis of
myeloma cells; overcomes cytokine and bone marrow
stromalcell-mediateddrugresistance;hasantiangiogenic
effects; enhances dexamethasone cytotoxicity; and
stimulates host anti-myeloma T-cell and natural killer
(NK)-cellimmunity[1].Frequenttoxicitiesoflenalidomide
areneutropenia,deepveinthrombosis(includingpulmon-
ary embolism), thrombocytopenia, anemia, pneumonia,
atrial fibrillation, fatigue, and diarrhea [2].
The aim of our study was to evaluate the efficacy of
treatment of patients with relapsed and refractory mul-
tiple myelomas who could not be treated with the usual
dose of lenalidomide (25 mg per day, for 21 days in a
28 day cycle). We administered lenalidomide in reduced
doses depending on the severity of contraindication.
Patients and methods
Patients
This was a clinical trial in patients with relapsed and re-
fractory multiple myeloma. In retrospect we investigated
patients between June 2007 and December 2009 who
weretreatedattheUniversityHospitalinBonn,Germany.
Ten patients with refractory or recurrent myeloma were
registered. The performance of the study was in con-
sensus with the Declaration of Helsinki of 2000. The
EthicsReviewCommitteeapprovedtheprotocol,patients'
information and the declaration of consent.
Patient eligibility criteria
We observed patients with relapsed and refractory mul-
tiplemyelomawho,forvariousreasons(seebelow),could
notbetreatedwiththeusualdoseoflenalidomideduring
the whole duration of treatment. Two patients started
with a reduced dose, eight patients required a dose re-
duction during the therapy. They all were aged ≥18 years
and had received at least two prior treatment regimens.
Treatment
On days 1 to 21 of a cycle of 28 days lenalidomide was
administered once a day at doses between 5 and 25 mg.
When the adverse events were limitative the dose was
reduced,whentheywereregressivethedosewaspartially
augmentedagain.Lenalidomidewasgivenincombination
with dexamethasone which was administered at a mean
(median) dose of 17.6 (28) mg per day on days 1–4,
9–12 and 17–20. The dose of dexamethason was also
adapted to the tolerance.
Assessment of study outcomes
The response was evaluated every two to six weeks (in
one patient with the non-secretory MM after 3 month).
Theprimaryefficacyendpointwasachievementofatleast
a partial response (complete response [CR] + partial re-
sponse[PR]).Secondaryendpointsincludedassessment
of overall response rate (ORR, defined as CR + PR +
minimal response [MR]), progression-free survival (PFS),
time-to-progression (TTP), overall survival (OS), CR, PR,
MR, stable disease (SD), progressive disease (PD), dura-
tion of response safety and the mean given dose.
Investigatorevaluatedresponsewasassessedaccording
to the International Myeloma Working Group uniform re-
sponse criteria for multiple myeloma [3]. ORR was calcu-
latedasCR+PR+MRasrecommendedbytheAmerican
Society of Hematology/US Food and Drug Administration
Workshop on Clinical Endpoints in Multiple Myeloma [4].
Durationofresponsewasmeasuredfromthetimeofbest
response to progression of disease, for patients without
disease progression the duration of response was
measured from the time of best response to the time of
data collection. TTP is estimated as the time from the
start of lenalidomide treatment to disease progression,
with death due to causes other than progression. PFS
was assessed from start of the treatment to disease
progression or death (regardless of cause of death). OS
is defined as the time from the start of lenalidomide to
death due to any cause. Mean dose was calculated as
the midpoint of the mean doses of every single patient.
Adverse events were graded according to Common Ter-
minology Criteria for Adverse Events (Version 4.0). The
adverse event which was responsible for dose reduction
was accentuated.
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Due to the small collective of patients the probability of
a response in each category was not estimated but the
absolute numbers were reported. For OS and PFS the
Kaplan-Meier procedure was used to characterize the
survivalfunction.Thedevelopingofthespecificimmuno-
globulins and of the mean dose was demonstrated in a
line graph that includes the representation of standard
error.
To evaluate the impact of prognostic factors on response
to a lower dose of lenalidomide crosstabulators were
constructed using age (≤65 years, >65 years), gender,
prior stem cell therapy, prior anti multiple myeloma regi-
mens, prior radiotherapy, prior thalidomide treatment,
mean dose of lenalidomide and mean duration of treat-
ment.
Results
Patient characteristics
Baselinedemographicanddisease-relatedcharacteristics
ofpatientsareshowninTable1.Themean(median)time
from diagnosis was 4.8 (4.8) years (range 0.5–8.6). All
patients received at least two treatment regimens, while
fivepatientshadatleastthreepriortreatmentregimens.
Seven patients had received a prior autologous stem cell
transplantation. Overall, seven patients had received
prior treatment with thalidomide, eight with idarubicin,
seven with melphalan and four with bortezomib. All
10patientsreceivedareduceddoseoflenalidomidedue
to the following causes: Leukopenia (4), polyneuropathy
(1),musclecramps(1),thrombocytopenia(1),renalinsuf-
ficiency(1),attherequestofpatient(1)orascontinuous
therapy (1). Two of them started with a reduced dose,
eight of them achieved a dose reduction during the ther-
apy (Table 2). The mean (median) daily dose of lenalido-
midewas14(15)mg(range5–21.5mg),Figure1shows
the development of dose reduction. The mean (median)
timetofirstdosereductionwas4.8(3.5)monthsandthe
mean (median) duration of treatment was 15.1 (15)
months (Table 1). All patients were investigated with re-
gard to efficacy and toxicity.
Efficacy
The primary end point of CR + PR was achieved in seven
patients, including one patient with CR and six patients
with PR. One patient had a MR giving an ORR (CR + PR
+MR)ofeightpatients.Thetreatmentofonepatientwas
stopped after two months due to a clinical progression.
Mean(median)timetofirstresponseaftertreatmentwith
lenalidomide was 41.1 (30) days. The mean (median)
duration of response for patients who experienced a CR,
PR or MR was 9.1 (4.5) months. The development of
specific immunoglobulins is shown in Figure 2.
Table 1: Patient characteristics (n=10)
Figure 1: Mean dose of lenalidomide
Response results were analyzed according to pretreat-
ment: ≤ two versus ≥ three prior anti-MM treatment regi-
mensandofpatientswithpriortreatmentofthalidomide
or bortezomib (Table 3).
Differentiating according to the mean daily dose there is
one patient with a mean daily dose ≤5 mg. He achieved
a MR. Two of four patients who received doses between
15 and 20 mg had a PD. Those who achieved a PR re-
ceiveddosesbetween5and25mg(Table4).Thepatient
with CR had a mean dose of 17.5 mg (Table 2). At the
time of best response the two patients with PD received
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Figure 2: Development of specific immunoglobulins (IgG, IgA, free kappa light chains) for every patient excluded one patient
with a non-secretory multiple myeloma. Lc, light chain.
Table 3: Response rates to lenalidomide therapy. Response criteria according to International Myeloma Working Group.
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Table 5: Progression-free survival and time-to-progression
10 respectively 25 mg of lenalidomide, the one with MR
5 mg, the one with CR 25 mg. Those patients who
achieved a PR received in time of best response in five
cases 25 mg and in one case 15 mg (Table 2).
Mean(median)TTPandmean(median)PFSwere8.7(4)
months (Table 5, Figure 3). For those patients who
achieved CR, PR or MR mean (median) TTP and mean
(median) PFS were 10.5 (5) months. All patients we re-
gistered were still alive at the time of data collection (OS,
Figure 4).
Figure 3: Kaplan-Meier plot of progression-free survival
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Toxicity
Details of treatment-related hematological toxicities are
shown in Table 6. Toxicity was distinguished between
hematologicalandnon-hematologicaltoxicity.Inhemato-
logical toxicities neutropenia was reported in eight pa-
tients(gradesIII+IVforthreepatients),thrombocytopenia
in7patients(gradesIII+IVforthreepatients)andanemia
in ten patients (grades III+IV for two patients). In two
cases the application of granulocyte-colony stimulating
factor was necessary, three patients obtained red blood
cell transfusions. After dose reduction of lenalidomide
the anemia, thrombocytopenia and leukopenia were
stable or even regressive.
Table 6: Hematologic adverse events
Innon-hematologicaltoxicitiesthemostfrequentlyreport-
ed adverse events were backpain (5), polyneuropathy
(3), muscle cramps (2), obstipation, pruritus. Polyneuro-
pathy was preexistant in all cases at the beginning of
therapy with lenalidomide due to a prior treatment with
thalidomide, bortezomib or vincristine. In one patient
polyneuropathy worsened during therapy and necessi-
tated a dose reduction. This patient had previously re-
ceived thalidomide for 10 months (with significant peri-
pheral and central neuropathy), then bortezomib for
15 months (with painful neuropathy) and then lenalido-
mide for 16 months (with paresthesia).
Reasons for change of lenalidomide
dose
As shown in Table 7 the most common reason for dose
reduction of lenalidomide was leukopenia (4 patients).
One patient needed a dose reduction due to muscle
cramps,onepatientduetopolyneuropathy.Thrombocyto-
penialedtoadosereductioninonecaseaswellasrenal
insufficiency. One patient required the dose reduction,
anotheronegotaplanneddosereductionforcontinuous
therapy.
Table 7: Reasons for dose reduction
Discussion
Patientswithrecurrentorrefractorymyelomahaveapoor
prognosis. Lenalidomide is an effective therapy for pa-
tientswithrelapsedandrefractorymultiplemyeloma.We
evaluated that it is also effective even if a dose reduction
is necessary. It allows the treatment of selected patients
who otherwise would be excluded from a treatment with
lenalidomide.
Given that the dose reductions were effected at different
momentstherelationbetweenresponseratesandmean
dose is limited. There were three patients whose dose
hadbeenreducedbeforethefirstresponse.Fivepatients
were treated with a reduced dose initiated after first re-
sponse was achieved (three of them did not have a pro-
gressionyet).Twopatients,whohadprogressed,received
lenalidomide leading to a stable disease. After obtaining
stable disease the dose of lenalidomide was reduced
leading to a continuation of stable disease.
Overallresponserateswereinalmostallsubgroups60%,
independent of number or character of prior treatment
regimens. The mean daily dose of all patients who
achieved a response (at least MR) was 13.5 mg.
The overall mean (median) PFS value for all patients
treated with reduced dose of lenalidomide was 8.7 (4)
months; for those who achieved at least PR it was 11.1
(4)months.ThepatientwithaMRdidnothaveaprogres-
sion yet after six months of therapy. After duration of
treatment between 1 and 29 months (mean (median)
value of 15.9 (15) months) all patients were still alive.
In newly diagnosed multiple myeloma one-year PFS and
overall response rates were superior with lenalidomide
plus dexamethasone as compared to dexamethasone
alone (78% vs. 52%, P=.002; 78% vs. 48%, P<.001) [5].
In addition, lenalidomide plus low-dose dexamethasone
is associated with better short-term OS and with lower
toxicitythanlenalidomideplushigh-dosedexamethasone
in patients with newly diagnosed myeloma [6]. Another
study suggests the superiority of lenalidomide/dexa-
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intermsofresponserates,survival,andtoxicity[7].There
was also found a median TTP of 22.3 and 27.4 months
and a median PFS of 19.1 and 26.7 months [6], [7].
Acombinedtherapyofdexamethasoneandlenalidomide
(in a dose of 25 mg) for relapsed multiple myeloma pro-
duced an overall response of 60.2–61%, a median OS
of 29.6 to 38 months and a median TTP of 11.1 to 13.4
months [8], [9], [10].
These results in a small patient sample indicate that in
selected patients' therapy with a reduced dose of lena-
lidomidecanbeasafeandeffectivealternativeforselect-
ed patients who may not tolerate full doses.
Themostfrequentlyreasonfordosereductionwasleuko-
penia (four patients). The myelosuppression was control-
lable with dose reduction or granulocyte-colony stimulat-
ing factor (necessary in two cases).
Inconclusion,dosereductionoflenalidomidewasfeasible
and seemed to be effective in relapsed or refractory my-
eloma patients who cannot tolerate normal doses. Cer-
tainlyitcannotberecommendedgenerallytogivealower
dose of lenalidomide, but in selected cases it can be a
possibility to treat patients who otherwise would be ex-
cluded from treatment with lenalidomide.
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